OBJECTIVE: The purpose of this study was to estimate and compare the effects of
antipsychotics—both the newer ones and the conventional ones—on body weight …

In this issue of Structure, Holmes et al.(2005) describe elements of an innate defense
mechanism that provides mammals a means to restrict bacterial growth. The host protein …

OBJECTIVE: The goal of this 5-year naturalistic study of patients treated with clozapine was
to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors …

With the availability of the so-called novel antipsychotic agents, extrapyramidal symptoms
are becoming decreasingly problematic for patients with schizophrenia, and simultaneously …

People with schizophrenia may be at increased risk for Type II diabetes because of the side
effects of antipsychotic medication, poorer overall physical health, less healthy lifestyles, and …

OBJECTIVE: The development of both type I and type II diabetes after initiation of some
atypical neuroleptics has been reported, primarily in studies involving small series of …

Background Hyperglycemia and type 2 diabetes mellitus are more common in
schizophrenia than in the general population. Glucoregulatory abnormalities have also been …

Context Weight gain, a common adverse effect of antipsychotic medications, is associated
with medical comorbidities in psychiatric patients. Objective To test the efficacy of lifestyle …

Body weight gain frequently occurs during drug treatment of psychiatric disorders and is
often accompanied by increased appetite or food craving. While occurrence and time course …

▪ Abstract “Atypical” antipsychotics represent a new generation of antipsychotics with a
significantly lower incidence of extrapyramidal side effects (EPS), as well as little or no effect …